Malignant mesothelioma

Community Oncology

Volumn 3, Issue 4, 2006, Pages 215-224

  Gadgeel, Shirish M ^a,c,d,e,f   Pass, Harvey I ^b,f,g  

^a WAYNE STATE UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e GENENTECH INC   (United States)

^f Sanofi Aventis   (United States)

^g Eli Lilly ^*

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTINEOPLASTIC AGENT; ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; METHOTREXATE; PACLITAXEL; PEMETREXED; RALTITREXED; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOGENETICS; DISEASE COURSE; DRUG SCREENING; ELECTRON MICROSCOPY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MOLECULAR BIOLOGY; PATHOLOGY; PLEURA MESOTHELIOMA; PROGNOSIS; RADIODIAGNOSIS; REVIEW; RISK FACTOR; SEROSA;

EID: 33646013866     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70685-4     Document Type: Review

References (83)

1. Peto J, DeCarli A, La VC, LaVecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999;79:666-672.
2. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data from 1973 through 2003. Am J Epidemiol 2004;159:107-112.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960,17:260-271.
4. Peto J, Seidman H, Selikoff IJ. Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer 1982;45:124-135.
5. Selikoff IJ, Seidman H. Asbestos-associated deaths among insulation workers in the United States and Canada, 1967-1987. Ann N Y Acad Sci 1991;643:1-14.
6. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723-731.
7. Yates DH, Corrin B, Stidolph PN, Browne K. Malignant mesothelioma in southeast England: clinicopathological experience of 272 cases. Thorax 1997;52:507-512.
8. Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma: the University of Minnesota experience. Cancer 1984;53:377-383.
9. Li FP, Lokich J, Lapey J, Neptune WB, Wilkins EW Jr. Familial mesothelioma after intense asbestos exposure at home. JAMA 1978;240:467.
10. Anderson HA, Lilis R, Daum SM, Fischbein AS, Selikoff IJ. Household-contact asbestos neoplastic risk. Ann N Y Acad Sci 1976;271:311-323.
11. McDonald JC, McDonald AD, Hughes JM. Chrysotile tremolite and fibrogenicity. Ann Occup Hyg 1999;43:439-442.
12. Landrigan PJ, Nicholson WJ, Suzuki Y, Ladou J. The hazards of chrysotile asbestos: a critical review. Ind Health 1999;37:271-280.
13. Cullen MR. Chrysotile asbestos: enough is enough. Lancet 1998;351:1377-1378.
14. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences human pleural mesothelioma. Oncogene 1994;9:1781-1790.
15. Bocchetta M, DiResta I, Powers A, et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc Natl Acad Sci USA 2000;97:10214-10219.
16. Rizzo P, Di Resta I, Powers A, Ratner H, Carbone M. Unique strains of SV40 in commercial polio vaccines from 1955 not readily identifiable with current testing for SV40 infection. Cancer Res 1999;59:6103-6108.
17. Strickler HD, Goedert JJ, Devesa SS, Lahey J, Fraumeni JF Jr, Rosenberg PS. Trends in US pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 2003;95:38-45.
18. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. J Cell Physiol 1999;180:150-157.
19. Testa JR, Pass HI, Carbone M. Molecular biology of mesothelioma. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001:1937-1943.
20. Owens MW, Milligan SA. Growth factor modulation of rat pleural mesothelial cell mitogenesis and collagen synthesis: effects of epidermal growth factor and platelet derived growth factor. Inflammation 1994;18:77-87.
21. Gerwin BI, Lechner JF, Reddel RR, et al. Comparison of production of transforming growth factor-beta and platelet derived growth factor by normal human mesothelial cells and mesothelial cell lines. Cancer Res 1987;47:6180-6184.
22. Klominek J, Baskin B, Liu Z, Hauzenberger D. Hepatocyte growth factor/scatter factor stimulates chemotaxis and growth of malignant mesothelial cells through c-met receptor. Int J Cancer 1998;76:240-249.
23. Gasparini G, Harris AL. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995;13:765-782.
24. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-886.
25. Meert AP, Paesmans M, Martin B, et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002;87:694-701.
26. Kumar-Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 1997;182:211-216.
27. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29(suppl 16):10-14.
28. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB, Van Marck E. Angiogenesis cytokines in mesothelioma: a study of VEGF, FGF-1 and 2, and TGF beta expression. J Pathol 1999;189:72-78.
29. Chahinian AP, Pajak TF, Holland JF, Norton L, Ambinder RM, Mandel EM. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 1982;96:746-755.
30. Adams VI, Unni KK, Muhn JR, Jett JR, Ilstrup DM, Bernatz PE. Diffuse malignant mesothelioma of pleura: diagnosis and survival of 92 cases. Cancer 1986;58:1540-1551.
31. Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 1998;77:907-912.
32. Efremidis AP, Waxman JS, Chahinian AP. Association of lymphocytic neoplasia and mesothelioma. Cancer 1985;55:1056-1059.
33. Ross R, Dworsky P, Nichols P, et al. Asbestos exposure and lymphomas of the gastrointestinal tract and oral cavity. Lancet 1982;2:1118-1119.
34. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998;114:713-722.
35. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2003;126:11-16.
36. Benard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-1245.
37. Corson J, Pinkus GS. Cellular localization patterns of keratin proteins in pleural mesothelioma and metastatic adenocarcinomas; a diagnostic discriminant. Lab Invest 1991;64:114A.
38. Bedrossian CMW, Bonsib S, Moran CA. Differential diagnosis between mesothelioma and adenocarcinoma: a multimodal approach based on ultrastructure and immunohistochemistry. Semin Diagnos Pathol 1992;9:124-135.
39. Ordonez NG, Mackay B. The role of immunohistochemistry and electron microscopy in distinguishing epithelial mesothelioma of pleura from adenocarcinoma. Adv Anant Pathol 1996;5:273-282.
40. Rusch VW. The international mesothelioma interest group: a proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-1128.
41. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152.
42. Pass HI. Malignant pleural mesothelioma: surgical roles and novel therapies. Clin Lung Cancer 2001;3;102-117.
43. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117:54-63.
44. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg 1999;68:1799-1804.
45. Ball DL, Cruickshank DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience with special reference to radiotherapy. Am J Clin Oncol 1990;13:4-9.
46. Brady LW. Mesothelioma-role for radiation therapy. Semin Oncol 1981;8:329-334.
47. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;122:788-795.
48. Gupta V, Mychalczak BR, Krug L, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2005;63:1045-1052.
49. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-1017.
50. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992;12:1436-1442.
51. Kindler HL, Belani CP, Herndon JE 2nd, et al. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma: sequential phase II trials by the Cancer and Leukemia Group B. Cancer 1999;86:1985-1991.
52. Scagliotti G, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-1561.
53. Bueno R, Appasani K, Mercer H, Lester S, Sugarbaker D. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121:225-233.
54. Illei PB, Rusch VW, Zakowski MF, Ladanyi M. Homozygous deletion of CDKN2A and codeletion of methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108-2113.
55. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985;69:1431-1432.
56. Lerner HJ, Schoenfeld DA, Martin A, Falkson G, Borden E. Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983;52:1981-1985.
57. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000;18:243-245.
58. Baas P, van Meerbeeck J, Groen H, et al. Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000;11:697-700.
59. Skubitz KM. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma. Cancer Invest 2002;20:693-699.
60. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711-712.
61. Zidar BL, Green S, Pierce HI, Roach RW, Balcerzak SP, Militello L. A phase II study evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988;6:223-226.
62. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239-242.
63. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8:151-154.
64. Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311-317.
65. van Meerbeeck JP, Baas P, Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577-2582.
66. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74:961-963.
67. Vogelzang NJ, Herndon JE, Miller A, et al. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999;10:597-600.
68. Vorobiof DA, Rapoport BL, Chasen MR, et al. Malignant pleural mesothelioma: a phase II trial with docetaxel. Ann Oncol 2002;13:412-415.
69. Vogelzang NJ, Rusthoven JJ Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2644.
70. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
71. Manegold C, Symanowski J, Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005;16:923-927.
72. th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, Ill. Abstract 2535.
73. th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 3007.
74. st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7019.
75. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 2002;29:41-50.
76. van Ruth S, Bass P, Haas RLM, Rutgers EJTh, Verwaal VJ, Zoetmulder FAN. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003;10:176-182.
77. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451-3457.
78. Cocco P, Dosemeci M. Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix. Am J Ind Med 1999;35:9-14.
79. Sugarbaker PH, Welch LS, Mohamed F, Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003;12:605-621, xi.
80. Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 2003;83:147-153.
81. st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, Fla. Abstract 7174.
82. Le DT, Deavers M, Hunt K, Malpica A, Verschraengen CF. Cisplatin and irinotecan (CPT-11) for peritoneal mesothelioma. Cancer Invest 2003;21:682-689.
83. Kerrigan SA, Turnnir RT, Clement PB, Young RH, Churg A. Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients. Cancer 2002;94:378-385.